The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

		IES AND EXCHANG ngton, D.C. 20549 FORM D pt Offering of Secur		OMB APPROVAL OMB Number: 3235-0076 Estimated average burden hours per response: 4.00
1. Issuer's Identity				
CIK (Filer ID Number)	Previous Names	None	Entity Type	
0001279704	NOVELOS T	HERAPEUTICS, INC.	X Corporation	
Name of Issuer		IORIZONS INC	Limited Partnersh	ip
Cellectar Biosciences, Inc.	Novelos Ther	apeutics, Inc.		
Jurisdiction of Incorporation/Org	ganization Common Hor	izons Inc.	Limited Liability C	
DELAWARE			General Partnersh	nip
Year of Incorporation/Organiza	lion		Business Trust	
X Over Five Years Ago			Other (Specify)	
Within Last Five Years (Spe	cify Year)			
Yet to Be Formed				
2. Principal Place of Business	and Contact Information			
Name of Issuer				
Cellectar Biosciences, Inc.				
Street Address 1		Street Address 2		
100 CAMPUS DRIVE		SUITE 207		
City	State/Province/Country	ZIP/PostalCode	Phone Number of Is	ssuer
FLORHAM PARK	NEW JERSEY	07932	(608) 441-8120	
3. Related Persons				
Last Name	First Name		Middle Name	
Caruso	James		V.	
Street Address 1	Street Address 2			
100 Campus Drive	Suite 207			
City	State/Province/Co	untry	ZIP/PostalCode	
Florham Park	NEW JERSEY		07932	
Relationship: X Executive Offic	er X Director Promoter			
Clarification of Response (if Neo	cessary):			
Last Name	First Name		Middle Name	
Kolean	Chad		J.	
Street Address 1	Street Address 2			
100 Campus Drive	Suite 207			
City	State/Province/Co	untry	ZIP/PostalCode	
Florham Park	NEW JERSEY		07932	
Relationship: X Executive Offic				
Clarification of Response (if Neo	cessary):			
Last Name	First Name		Middle Name	
Longcor	Jarrod			
Street Address 1	Street Address 2			
100 Campus Drive	Suite 207			
City	State/Province/Co	untry	ZIP/PostalCode	
r Iornam Park	NEW JERSEY		07932	
Florham Park Relationship: X Executive Office			07932	

Clarification of Response (if Necessary):

,			
Last Name	First Name	Middle Name	
Lea	Darrell	Shane	
Street Address 1	Street Address 2	Share	
100 Campus Drive	Suite 207		
^		7IP/PaotalCodo	
City	State/Province/Country	ZIP/PostalCode	
Florham Park	NEW JERSEY	07932	
Relationship: X Executive Officer Director	Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Shustov	Andrei		
Street Address 1	Street Address 2		
100 Campus Drive	Suite 207		
City	State/Province/Country	ZIP/PostalCode	
Florham Park	NEW JERSEY	07932	
Relationship: X Executive Officer Director	Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Swirsky	Douglas	J.	
Street Address 1	Street Address 2		
100 Campus Drive	Suite 207		
City	State/Province/Country	ZIP/PostalCode	
Florham Park	NEW JERSEY	07932	
Relationship: Executive Officer X Director	Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Chanan-Kahn	Asher	Alban	
Street Address 1	Street Address 2		
Cellectar Biosciences, Inc.	100 Campus Drive		
City	State/Province/Country	ZIP/PostalCode	
Florham Park	NEW JERSEY	07932	
Relationship: Executive Officer X Director	Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Driscoll	Frederick	W.	
Street Address 1	Street Address 2		
100 Campus Drive	Suite 207		
City	State/Province/Country	ZIP/PostalCode	
Florham Park	NEW JERSEY	07932	
Relationship: Executive Officer X Director	Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Loren	Stefan	D.	
Street Address 1	Street Address 2		
100 Campus Drive	Suite 207		
City	State/Province/Country	ZIP/PostalCode	
Florham Park	NEW JERSEY	07932	
Relationship: Executive Officer X Director	Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Neis	John		
Street Address 1	Street Address 2		
100 Campus Drive	Suite 207		
City	State/Province/Country	ZIP/PostalCode	

Florham Park

07932

Relationship: Executive Officer Director Promoter

Clarification of Response (if Necessary):

4.	Industry	Group

Agriculture Banking & Financial Services Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Is the issuer registered as	Health Care Health Care Health Insurance Hospitals & Physicians Pharmaceuticals Other Health Care Manufacturing	Retailing Restaurants Technology Computers Telecommunications Other Technology Travel
Other Banking & Financial Services Business Services Energy Coal Mining Electric Utilities	REITS & Finance	Tourism & Travel Services Other Travel Other
☐ Energy Conservation ☐ Environmental Services ☐ Oil & Gas		

Other Energy

5. Issuer Size

Revenue Range	OR A	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
X Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company A	act Section 3(c)
\Box Dulo 504/b)(1) (pot (i) (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)
Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)
Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)
Rule 504 (b)(1)(iii)	Section 3(c)(4)	Section 3(c)(12)
X Rule 506(b) Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)
	Section 3(c)(7)	

7. Type of Filing		
X New Notice Date of First Sale 2023-09-08 First Sale Yet to Occu	r	
8. Duration of Offering		
Does the Issuer intend this offering to last more than one year?	s <mark>X</mark> No	
9. Type(s) of Securities Offered (select all that apply)		
X Equity Debt X Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or Other F Acquire Security	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Right to X Other (describe) Includes shares of preferred stock to be issued upon exercise of	warrants.
10. Business Combination Transaction		
Is this offering being made in connection with a business combination to or exchange offer?	ransaction, such as a merger, acquisition \Box Yes X No	
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside investor \$84,400 USD		
12. Sales Compensation		
Recipient	Recipient CRD Number None	
Oppenheimer & Co. Inc.	249	
(Associated) Broker or Dealer \overline{X} None	(Associated) Broker or Dealer CRD Number $\overline{\mathrm{X}}$ None	
None Street Address 1	None	
85 BROAD STREET	Street Address 2	
City	State/Province/Country	ZIP/Postal Code
NEW YORK State(s) of Solicitation (select all that apply)		10004
Check "All States" or check individual States	Foreign/non-US	
CALIFORNIA		
CONNECTICUT		
MARYLAND		
NEVADA		
NEW YORK		
NORTH CAROLINA TEXAS		
13. Offering and Sales Amounts		
Total Offering Amount \$24,500,000 USD or Indefinite		
Total Amount Sold \$24,500,000 USD		
Total Remaining to be Sold \$0 USD or Indefinite		
Clarification of Response (if Necessary):		
14. Investors		
Select if securities in the offering have been or may be sold to perso		er of
L such non-accredited investors who already have invested in the offer Regardless of whether securities in the offering have been or may b total number of investors who already have invested in the offering:	be sold to persons who do not qualify as accredited investors, enter	the 21
15. Sales Commissions & Finder's Fees Expenses		
Provide separately the amounts of sales commissions and finders fees	expenses, if any. If the amount of an expenditure is not known, prov	vide an estimate and

check the	box	next	to	the	amount.
-----------	-----	------	----	-----	---------

Sales Commissions \$1,3	72,000 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds		

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.



Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Cellectar Biosciences, Inc.	/s/ Chad J. Kolean	Chad J. Kolean	Chief Financial Officer	2023-09-22

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.